S100A7 (psoriasin) is induced by the proinflammatory cytokines oncostatin-M and interleukin-6 in human breast cancer

Oncogene

Volumn 29, Issue 14, 2010, Pages 2083-2092

  West, N R ^a,b   Watson, P H ^a,b,c  

^a BRITISH COLUMBIA CANCER AGENCY   (Canada)

^b UNIVERSITY OF VICTORIA   (Canada)

^c UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Breast cancer; Cytokines; Inflammation; S100A7

Indexed keywords

CYTOKINE; INTERLEUKIN 6; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; ONCOSTATIN M; ONCOSTATIN M RECEPTOR BETA; PHOSPHATIDYLINOSITOL 3 KINASE; PSORIASIN; SMALL INTERFERING RNA; STAT3 PROTEIN;

ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CYTOKINE RELEASE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SKIN INFLAMMATION;

ANIMALS; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL MOVEMENT; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INFLAMMATION; INTERLEUKIN-6; ONCOSTATIN M; S100 PROTEINS; SIGNAL TRANSDUCTION; TIME FACTORS;

EID: 77950860642     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2009.488     Document Type: Article

References (53)

1. Al-Haddad S, Zhang Z, Leygue E, Snell L, Huang A, Niu Y et al. (1999). Psoriasin (S100A7) expression and invasive breast cancer. Am J Pathol 155: 2057-2066.
2. Badache A, Hynes NE. (2001). Interleukin 6 inhibits proliferation and, in cooperation with an epidermal growth factor autocrine loop, increases migration of T47D breast cancer cells. Cancer Res 61: 383-391.
3. Balkwill F, Charles KA, Mantovani A. (2005). Smoldering and polarized inflammation in the initiation and promotion of malignant disease. Cancer Cell 7: 211-217.
4. Bando M, Hiroshima Y, Kataoka M, Shinohara Y, Herzberg MC, Ross KF et al. (2007). Interleukin-1a regulates antimicrobial peptide expression in human keratinocytes. Immunol Cell Biol 85: 532-537.
5. Boniface K, Bernard F, Garcia M, Gurney AL, Lecron J, Morel F. (2005). IL-22 inhibits epidermal differentiation and induces proinflammatory gene expression and migration of human keratinocytes. J Immunol 174: 3695-3702.
6. Boniface K, Diveu C, Morel F, Pedretti N, Froger J, Ravon E et al. (2007). OncostatinMsecreted by skin infiltrating T lymphocytes is a potent keratinocyte activator involved in skin inflammation. J Immunol 178: 4615-4622.
7. Conze D, Weiss L, Regen PS, Bhushan A, Weaver D, Johnson P et al. (2001). Autocrine production of interleukin 6 causes multidrug resistance in breast cancer cells. Cancer Res 61: 8851-8858.
8. Daur DJ, Ferraro B, Song L, Yu B, Mora L, Buettner R et al. (2005). Stat3 regulates genes common to both wound healing and cancer. Oncogene 24: 3397-3408.
9. de Visser KE, Eichten A, Coussens LM. (2006). Paradoxical roles of the immune system during cancer development. Nature Rev Cancer 6: 24-37.
10. Di Nuzzo S, Sylva-Steenland RMR, Koomen CW, de Rie MA, Das PK, Bos JD et al. (2000). Exposure to UVB induces accumulation of LFA-1+ T cells and enhanced expression of the chemokine psoriasin in normal human skin. Photochem Photobiol 72: 374-382.
11. Emberley ED, Alowami S, Snell L, Murphy LC, Watson PH. (2004a). S100A7 (psoriasin) expression is associated with aggressive features and alteration of Jab1 in ductal carcinoma in situ of the breast. Breast Cancer Res 6: R308-R315. (http://breast-cancer-research. com/content/6/4/R308).
12. Emberley ED, Murphy LC, Watson PH. (2004b). S100A7 and the progression of breast cancer. Breast Cancer Res 6: 153-159. (http:// breast-cancer-research. com/content/6/4/153).
13. Emberley ED, Niu Y, Curtis L, Troup S, Mandal SK, Myers JN et al. (2005). The S100A7-c-Jun activation domain binding protein 1 pathway enhances prosurvival pathways in breast cancer. Cancer Res 65: 5696-5702.
14. Emberley ED, Niu Y, Leygue E, Tomes L, Gietz RD, Murphy LC et al. (2003a). Psoriasin interacts with Jab1 and influences breast cancer progression. Cancer Res 63: 1954-1961.
15. Emberley ED, Niu Y, Njue C, Kliewer EV, Murphy LC, Watson PH. (2003b). Psoriasin (S100A7) expression is associated with poor outcome in estrogen receptor-negative invasive breast cancer. Clin Cancer Res 9: 2627-2631.
16. Enerbä ck C, Porter DA, Seth P, Sgroi D, Gaudet J, Weremowicz S et al. (2002). Psoriasin expression in mammary epithelial cells in vitro and in vivo. Cancer Res 62: 43-47.
17. Gaffen SL. (2008). An overview of IL-17 function and signaling. Cytokine 43: 402-407.
18. Gazel A, Rosdy M, Bertino B, Tornier C, Sahuc F, Blumenberg M. (2006). A characteristic subset of psoriasis-associated genes is induced by oncostatin-M in reconstituted epidermis. J Invest Dermatol 126: 2647-2657.
19. Grant SL, Hammacher A, Douglas AM, Goss GA, Mansfield RK, Heath JK et al. (2002). An unexpected biochemical and functional interaction between gp130 and the EGF receptor family in breast cancer cells. Oncogene 21: 460-474.
20. Grivennikov S, Karin M. (2008). Autocrine IL-6 signaling: a key event in tumorigenesis? Cancer Cell 13: 7-9.
21. Heinrich PC, Behrmann I, Haan S, Hermanns HM, Müller-Newen G, Schaper F. (2003). Principles of interleukin (IL)-6-type cytokine signalling and its regulation. Biochem J 374: 1-20.
22. Herschkowitz JI, Simin K, Weigman VJ, Mikaelian I, Usary J, Hu Z et al. (2007). Identification of conserved gene expression features between murine mammary carcinoma models and human breast tumors. Genome Biol 8: R76. (http://genomebiology.com/2007/8/5/ R76).
23. Holzer RG, Ryan RE, Tommack M, Schlekeway E, Jorcyk CL. (2004). Oncostatin M stimulates the detachment of a reservoir of invasive mammary carcinoma cells: role of cyclooxygenase-2. Clin Exp Met 21: 167-176.
24. Hsu K, Passey RJ, Endoh Y, Rahimi F, Youssef P, Yen T et al. (2005). Regulation of S100A8 by glucocorticoids. J Immunol 174: 2318-2326.
25. Jinquan T, Vorum H, Larsen CG, Madsen P, Rasmussen HH, Gesser B et al. (1996). Psoriasin: a novel chemotactic protein. J Invest Dermatol 107: 5-10.
26. Jorcyk CL, Holzer RG, Ryan RE. (2006). Oncostatin M induces cell detachment and enhances the metastatic capacity of T-47D human breast carcinoma cells. Cytokine 33: 323-336.
27. Kennedy RD, Gorski JJ, Quinn JE, Stewart GE, James CR, Moore S et al. (2005). BRCA1 and c-Myc associate to transcriptionally repress psoriasin, a DNA damage-inducible gene. Cancer Res 65: 10265-10272.
28. Knüpfer H, Prei R. (2007). Significance of interleukin-6 (IL-6) in breast cancer (review). Breast Cancer Res Treat 102: 129-135.
29. Krop I, Mä rz A, Carlsson H, Li X, Bloushtain-Qimron N, Hu M et al. (2005). A putative role for psoriasin in breast tumor progression. Cancer Res 65: 11326-11334.
30. Liang SC, Tan XY, Luxenberg DP, Karim R, Dunussi-Joannopoulos K, Collins M et al. (2006). Interleukin (IL)-22 and IL-17 are coexpressed by Th17 cells and cooperatively enhance expression of antimicrobial peptides. J Exp Med 203: 2271-2279.
31. Liu J, Hadjokas N, Mosley B, Estrov Z, Spence MJ, Vestal RE. (1998). Oncostatin M-specific receptor expression and function in regulating cell proliferation of normal and malignant mammary epithelial cells. Cytokine 10: 295-302.
32. Modur V, Feldhaus MJ, Weyrich AS, Jicha DL, Prescott SM, Zimmerman GA et al. (1997). Oncostatin M is a proinflammatory mediator. in vivo effects correlate with endothelial cell expression of inflammatory cytokines and adhesion molecules. J Clin Invest 100: 158-168.
33. Mosser DM, Edwards JP. (2008). Exploring the full spectrum of macrophage activation. Nat Rev Immunol 8: 958-969.
34. Naka T, Nishimoto N, Kishimoto T. (2002). The paradigm of IL-6: from basic science to medicine. Arthritis Res 4: S233-242.
35. Paruchuri V, Prasad A, McHugh K, Bhat HK, Polyak K, Ganju RK. (2008). S100A7-downregulation inhibits epidermal growth factor induced signaling in breast cancer cells and blocks osteoclast formation. PLoS One 3: e1741.
36. Perrier S, Caldefie-Chézet F, Vasson M. (2008). IL-1 family in breast cancer: potential interplay with leptin and other adipocytokines. FEBS Lett 583: 259-265.
37. Pestka S, Krause CD, Sarkar D, Walter MR, Shi Y, Fisher PB. (2004). Interleukin-10 and related cytokines and receptors. Annu Rev Immunol 22: 929-979.
38. Petersson S, Bylander A, Yhr M, Enerbä ck C. (2007). S100A7 (psoriasin), highly expressed in ductal carcinoma in situ (DCIS), is regulated by IFN-gamma in mammary epithelial cells. BMC Cancer 7: 205.
39. Rivard CJ, Brown LM, Almeida NE, Maunsbach AB, Pihakaski- Maunsbach K, Andres-Hernando A et al. (2007). Expression of the calcium-binding protein S100A4 is markedly up-regulated by osmotic stress and is involved in the renal osmoadaptive response. J Biol Chem 282: 6644-6652.
40. Royuela M, Ricote M, Parsons MS, García-Tuñó n I, Paniagua R, De Miguel MP. (2004). Immunohistochemical analysis of the IL-6 family of cytokines and their receptors in benign, hyperplasic, and malignant human prostate. J Pathol 202: 41-49.
41. Sa SM, Valdez PA, Wu J, Jung K, Zhong F, Hall L et al. (2007). The effects of IL-20 subfamily cytokines on reconstituted human epidermis suggest potential roles of cutaneous innate defense and pathogenic adaptive immunity in psoriasis. J Immunol 178: 2229-2240.
42. Sansone P, Storci G, Tavolari S, Guarnieri T, Giovannini C, Taffurelli M et al. (2007). IL-6 triggers malignant features in mammospheres from human ductal breast carcinoma and normal mammary gland. J Clin Invest 117: 3988-4002.
43. Shain KH, Yarde DN, Meads MB, Huang M, Jove R, Hazlehurst LA et al. (2009). b1 integrin adhesion enhances IL-6-mediated STAT3 signaling in myeloma cells: implications for microenvironment influence on tumor survival and proliferation. Cancer Res 69: 1009-1015.
44. Skliris GP, Lewis A, Emberley E, Peng B, Weebadda WK, Kemp A et al. (2007). Estrogen receptor-b regulates psoriasin (S100A7) in human breast cancer. Breast Cancer Res Treat 104: 75-85.
45. Tanaka M, Miyajima A. (2003). Oncostatin M, a multifunctional cytokine. Rev Physiol Biochem Pharmacol 149: 39-52.
46. Wang J, Barnes RO, West NR, Olson M, Chu JE, Watson PH. (2008). Jab1 is a target of EGFR signaling in ERa-negative breast cancer. Breast Cancer Res 10: R51. (http://breast-cancer-research.com/ content/10/3/R51).
47. Wen Z, Darnell Jr JE. (1997). Mapping of Stat3 serine phosphorylation to a single residue (727) and evidence that serine phosphorylation has no influence on DNA binding of Stat1 and Stat3. Nucleic Acids Res 25: 2062-2067.
48. Wolf R, Howard OM, Dong HF, Voscopoulos C, Boeshans K, Winston J et al. (2008). Chemotactic activity of S100A7 (psoriasin) is mediated by the receptor for advanced glycation end products and potentiates inflammation with highly homologous but functionally distinct S100A15. J Immunol 181: 1499-1506.
49. Wolk K, Witte E, Wallace E, Dö cke WD, Kunz S, Asadullah K et al. (2006). IL-22 regulates the expression of genes responsible for antimicrobial defense, cellular differentiation, and mobility in keratinocytes: a potential role in psoriasis. Eur J Immunol 36: 1309-1323.
50. Yang J, Liao X, Agarwal MK, Barnes L, Auron PE, Stark GR. (2007). Unphosphorylated STAT3 accumulates in response to IL-6 and activates transcription by binding to NFkB. Genes Dev 21: 1396-1408.
51. Zhang F, Li C, Halfter H, Liu J. (2003). Delineating an oncostatin Mactivated STAT3 signaling pathway that coordinates the expression of genes involved in cell cycle regulation and extracellular matrix deposition of MCF-7 cells. Oncogene 22: 894-905.
52. Zitvogel L, Tesniere A, Kroemer G. (2006). Cancer despite immunosuveillance: immunoselection and immunosubversion. Nature Rev Immunol 6: 715-727.
53. Zou W. (2005). Immunosuppressive networks in the tumour environment and their therapeutic relevance. Nat Rev Cancer 5: 263-274.